Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP-102 for the treatment of non-Hodgkin...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of HPHA.DE is 6.6 and suggests 118% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell